FAQ on Nutriband Inc.'s U.S. Patent for Abuse-Deterrent Transdermal Technology

What is the significance of Nutriband Inc.’s new U.S. patent?

The U.S. patent No. 12,318,492 strengthens domestic protection for Nutriband’s Aversa(TM) technology, which is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential through transdermal products.

What is Aversa(TM) technology?

Aversa(TM) is Nutriband’s abuse-deterrent technology that can be incorporated into any transdermal patch to prevent the abuse and misuse of drugs with abuse potential, currently being developed for the Aversa Fentanyl patch.

What is Nutriband’s lead product under development?

Nutriband’s lead product is Aversa Fentanyl, an abuse-deterrent fentanyl patch that aims to be the first of its kind on the market, with significant U.S. sales potential projected between $80 million and $200 million.

When was the U.S. patent for Aversa(TM) technology issued?

The U.S. patent for Aversa(TM) technology was issued on June 3, 2025.

Where can I find more information about Nutriband Inc.?

More information about Nutriband Inc. can be found on their website at www.Nutriband.com.

How does Aversa(TM) technology benefit the public?

Aversa(TM) technology benefits the public by providing a safer alternative to traditional transdermal patches, reducing the risk of drug abuse, misuse, and accidental exposure, particularly for drugs with high abuse potential like fentanyl.

What are the projected sales for Aversa Fentanyl?

Aversa Fentanyl has peak U.S. sales potential projected between $80 million and $200 million.

Where can I view the full article about Nutriband’s patent?

The full article can be viewed at https://ibn.fm/9bBiW.

Who can I contact for more information about BioMedWire?

For more information about BioMedWire, you can visit their website at https://www.biomedwire.com or email Editor@BioMedWire.com.